Drug intelligence / Profile preview

LycoMab

Development stage: Preclinical
Lead developer: Lycotec
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

LycoMab is a **preclinical monoclonal antibody** being developed by **Lycotec** for **prostate cancer**. Publicly available pipeline information identifies it as an antibody program in oncology, but does **not disclose a molecular target, epitope, antibody subclass, engineering format, or precise mechanism of action**. Based on the disclosed modality, LycoMab is best characterized as an investigational therapeutic antibody intended for antineoplastic use in prostate cancer, with mechanism and development details still largely undisclosed.

Targets

SCARB1 (Scavenger receptor class B member 1)

Beyond the preview

Go deeper on LycoMab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LycoMab.

Explore the full profile